Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague 2, Czech Republic.
J Clin Pharm Ther. 2022 Sep;47(9):1362-1367. doi: 10.1111/jcpt.13753. Epub 2022 Aug 7.
mTOR inhibitors possess narrow therapeutic range and substantial pharmacokinetic variability and the consequences from suboptimal dosing are serious. The aim of this review is to summarize the current knowledge about the factors influencing mTOR inhibitors pharmacokinetics and the possibility of using these relationships in order to improve its therapy individualization in solid organ transplanted patients.
Literature search from Pubmed and Web of Science databases were performed using Boolean search operators in order to identify relevant studies.
A total of 701 reports were identified from the initial literature search. Out of which 40 studies dealt with relationships between various factors and pharmacokinetics of mTOR inhibitors and with relevance of these associations for dosage optimization.
The overview of the current covariates for pharmacokinetic variability of mTOR inhibitors has been provided on the level of absorption, distribution and elimination, and consequences of these relationships for dosing optimization has been summarized.
mTOR 抑制剂具有狭窄的治疗范围和显著的药代动力学变异性，剂量不足的后果很严重。本综述的目的是总结影响 mTOR 抑制剂药代动力学的因素的现有知识，并探讨利用这些关系来改善实体器官移植患者个体化治疗的可能性。
使用布尔搜索运算符从 Pubmed 和 Web of Science 数据库中进行文献检索，以确定相关研究。
从最初的文献检索中确定了 701 份报告。其中 40 项研究涉及各种因素与 mTOR 抑制剂药代动力学之间的关系，以及这些关联对剂量优化的相关性。
提供了 mTOR 抑制剂药代动力学变异性的当前协变量概述，包括吸收、分布和消除水平，并总结了这些关系对剂量优化的影响。
